Sandip Patel, MD
Internal Medicine · Fayetteville, NCNPI 1750358222
Payments from drug & device makers
Across 387 payments — averaging $88.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$29K
- Novo Nordisk$900
- Lilly USA, LLC$498
- GSK$440
- Sanofi-aventis U.S. LLC$382
- Pfizer$372
- plus $3K from 26 others
What the payments were for
- Consulting fees$28,46983%
- Food & beverage$5,86517%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $28,876 |
| Novo Nordisk | 54 | $900 |
| Lilly USA, LLC | 32 | $498 |
| GSK | 27 | $440 |
| Sanofi-aventis U.S. LLC | 21 | $382 |
| Pfizer | 20 | $372 |
| Boehringer Ingelheim | 21 | $368 |
| AbbVie(2 entities) | 21 | $294 |
| Merck | 18 | $275 |
| Johnson & Johnson | 19 | $265 |
| Exact Sciences | 11 | $213 |
| Amarin Pharma, Inc. | 13 | $203 |
| Avanir Pharmaceuticals, Inc. | 28 | $202 |
| Novartis | 13 | $197 |
| Amgen | 12 | $183 |
| Philips North America LLC | 7 | $139 |
| Astellas Pharma US Inc | 3 | $124 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| Organogenesis Inc. | 2 | $60 |
| Abbott | 4 | $59 |
| Nestle Healthcare Nutrition Inc. | 2 | $41 |
| Edwards Lifesciences | 1 | $35 |
| Kowa Pharmaceuticals America, Inc. | 3 | $34 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| TMS Neurohealth Centers Inc. | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi | 1 | $22 |
| Bayer | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,420 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 137 | $194,431 |
| EliquisApixaban | 106 | $82,803 |
| JardianceEmpagliflozin | 74 | $72,033 |
| MounjaroTirzepatide | 63 | $71,393 |
| TrulicityDulaglutide | 39 | $52,586 |
| Humalog Kwikpen U-200Insulin Lispro | 34 | $51,340 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $46,001 |
| XareltoRivaroxaban | 24 | $36,946 |
| FarxigaDapagliflozin Propanediol | 30 | $29,174 |
| JanuviaSitagliptin Phosphate | 16 | $23,492 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $23,451 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $21,222 |
| MyrbetriqMirabegron | 25 | $19,964 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 26 | $19,568 |
| EntrestoSacubitril/Valsartan | 11 | $13,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $900 | $203,970148 claims |
| Lilly USA, LLCMounjaro, Trulicity | $498 | $123,979102 claims |
| PfizerEliquis | $372 | $82,803106 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $368 | $79,18889 claims |
| MerckJanuvia, Janumet Xr | $275 | $43,06042 claims |
| Johnson & JohnsonXarelto | $265 | $36,94624 claims |
| AstraZenecaFarxiga | $28,876 | $29,17430 claims |
| GSKTrelegy Ellipta | $440 | $23,45128 claims |
| Astellas Pharma US IncMyrbetriq | $124 | $19,96425 claims |
| NovartisEntresto | $197 | $13,57611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Fayetteville
- Nitin DesaiFayetteville$6.4M
- Daniel UbaFayetteville$1.2M
- Eugene WrightFayetteville$839K
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.